Meet Dr. Arendash
- The neuroscientist who developed TRFT
- Over 125 peer-reviewed scientific publications
- Associate Editor at Journal of Alzheimer’s Disease
- Six pre-clinical studies showing the ability of TRFT to prevent/reverse cognitive impairment in Alzheimer’s mice and improve cognition in normal mice
- Eight clinical papers demonstrating:
- the safety and ability of TRFT to stop and reverse AD cognitive decline
- the potential for TRFT to extend human longevity
- the ability of TRFT to increase toxin drainage out of the human brain and do so during wakefulness
- the potential for TRFT to induce brain tumor regression
- Founded NeuroEM Therapeutics, scientifically advancing the Company to its current position by being directly responsible for all of NeuroEM’s pre-clinical and clinical research, scientific research findings, published papers, patents/patent applications, and grants.
- Attained the first “Breakthrough” device designation by FDA against Alzheimer’s Disease with TRFT (MemorEM device)
- Received three NIH grants to investigate the potential of TRFT against AD
- Attained his Ph.D. from University of California San Francisco Medical School; Post-Doctoral Fellow at UCLA Brain Research Institute; Professor at University of South Florida/Florida Alzheimer’s Disease Research Center
Gary Arendash, Ph.D.
Why RF Longevity?
Through RF Longevity, Dr. Arendash has recently begun focusing his scientific and awareness efforts to expedite clinical trials/use of TRFT to enhance human longevity. Until now, the life extension potential of TRFT technology has not been actively asserted.
Requests for seminars/presentations by Dr. Arendash for any of the following topics should be made through the “Contact” tab:
- Extension of Human Lifespan Through Transcranial Radiofrequency Waves
- Therapeutic Use of Transcranial Radiofrequency Waves to Stop and Reverse Alzheimer’s Disease
- The Sub-Cellular Basis of Cognition: It’s Enhancement by Transcranial Radiofrequency Waves
